Anti-CD20 (Rituximab biosimilar - IgG4 isotype)
| Product | Unit size | Cat. code | Docs. | Qty. | Price | |
|---|---|---|---|---|---|---|
|
Anti-hCD20-hIgG4 Human CD20 (rituximab) antibody - Human IgG4 |
Show product |
100 µg 3 x 100 µg |
hcd20-mab4
|
|
Monoclonal human IgG4 antibody against human CD20
Anti-hCD20-hIgG4 features the constant region of the human IgG4 isotype and the variable region of rituximab.
Rituximab is a mouse/human chimeric monoclonal antibody that targets the CD20 antigen found on the surface of malignant and normal B lymphocytes.
Binding of rituximab to CD20 results in cell destruction through different mechanisms including direct signaling of apoptosis, complement activation and cell-mediated cytotoxicity.
Rituximab has been approved by the FDA for the treatment of various lymphoid malignancies, including B-cell non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukaemia.
Anti-hCD20-hIgG4 was generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography with protein G.
Back to the top
Specifications
Clonality: Monoclonal antibody
Specificity: Targets cells expressing human CD20
Isotype: Human IgG4, kappa
Back to the topContents
Anti-hCD20-hIgG4 purified monoclonal antibody is provided azide-free and lyophilized. It is available in two quantities:
- hcd20-mab4: 100 µg
- hcd20-mab4-03: 3 x 100 µg
Product is shipped at room temperature.
Upon receipt, store at -20°C.
Back to the top